osimertinib
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
osimertinib
Apr 23, 2024, 18:57 |
Insight
New Paper Alert! Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of the Literature
Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of…
Apr 13, 2024, 09:17 |
Societies
30 Posts Not To Miss From AACR24!
The AACR Annual Meeting 2024 was held from April 5th to 10th in San Diego,…
Apr 12, 2024, 11:46 |
Drugs
Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…
Apr 4, 2024, 13:34 |
Drugs
Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "NSCLC and anti-EGFR treatments…
Feb 28, 2024, 18:42 |
Drugs
Amalya Sargsyan: Excitement around osimertinib in the NSCLC community
Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn: "Huge…
Feb 23, 2024, 14:31 |
Blog
Rasika Bombatkar: The rejection of my application for adjuvant Osimertinib is disheartening to say the least
Rasika Bombatkar, Citizen Scientist at LUNGevity Foundation, cancer patient and advocate, shared on X: "AstraZeneca,…
Feb 17, 2024, 15:57 |
Insight
Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.
Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter: "Hot off…
Feb 7, 2024, 12:46 |
Blog
Amin Nassar presents the results of a multicenter retrospective cohort for osimertinib and durvalumab in unresectable EGFR-mutant NSCLC
Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X/Twitter: "1. Pumped to…
Feb 5, 2024, 11:27 |
Insight
Stephen V Liu: The optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
Jan 16, 2024, 05:48 |
Drugs
Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
1
2
All:
15
Posts:
1 - 10
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Facebook
RSS Feed
Twitter
Linkedin
Youtube